We ended down yesterday but I actually find the trading encouraging. There was a big move down early in the day and we spent the rest of the trading day grinding higher. We still ended lower but we had one hour of selling and the rest of the day was buying. If we can continue […]
September 28th Biotech Update
We built on the move yesterday but I sort of feel unsatisfied with it. Perhaps it would have been too much to ask for a rapid and clear bounce off of support but it was a start. I think the most important point would be to remain above the recent lows as anything below that […]
September 27th Biotech Update
Yesterday was a better day. The market was weak and yet the sector outperformed. That is quite the rare occasion. It had been such a brutal month, there was bound to be a day in which the selling eased. There was some news that could have driven the outperformance but was that simply an excuse […]
September 25th Biotech Update
I think teetering is the word I would use to describe the sector. While a lot of the poor performance is sector related, I see this as more of a broader market issue with risk off hitting the whole market and that impacts the sector as being a risky sector. We have both interest rates […]
Mailing List
Introduction
Overview
Founded in 2011, Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.
The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate.
Subscribe to Chimera Research Group and proceed with confidence.
